Form 4: Intellia Therapeutics Executive Eliana Clark Reports Sale of 405 Shares

Eliana Clark, EVP and Chief Technical Officer of Intellia Therapeutics, sold 405 shares of common stock at a price of $22.93 on July 1, 2024.

Summary

• On July 1, 2024, Eliana Clark, the EVP and Chief Technical Officer of Intellia Therapeutics, sold 405 shares of common stock.
• The sale price was $22.93 per share.
• Following the transaction, Ms. Clark directly owns 71,470 shares of Intellia Therapeutics.
• The shares sold were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 28, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive's stock sale. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to track executive sentiment and potential alignment with company performance.

Comparison to Industry Standards

• Executive stock sales are a common occurrence in publicly traded companies.
• The sale of 405 shares by Eliana Clark is a relatively small transaction compared to the overall trading volume of Intellia Therapeutics.
• Similar transactions are regularly reported by executives at comparable companies like CRISPR Therapeutics and Editas Medicine.

Stakeholder Impact

• The sale of shares by an executive could be perceived as a neutral event by shareholders, as it is a common practice.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates